Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
LCTX 
Lineage Cell Therapeutics Inc (LCTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: LCTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -59.2% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 93.85M USD | Price to earnings Ratio - | 1Y Target Price 4.17 |
Price to earnings Ratio - | 1Y Target Price 4.17 | ||
Volume (30-day avg) 1600843 | Beta 1.28 | 52 Weeks Range 0.40 - 1.56 | Updated Date 04/2/2025 |
52 Weeks Range 0.40 - 1.56 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.09 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-05 | When Before Market | Estimate -0.03 | Actual -0.01 |
Profitability
Profit Margin -195.9% | Operating Margin (TTM) -178.17% |
Management Effectiveness
Return on Assets (TTM) -12.53% | Return on Equity (TTM) -26.73% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 48563435 | Price to Sales(TTM) 9.88 |
Enterprise Value 48563435 | Price to Sales(TTM) 9.88 | ||
Enterprise Value to Revenue 5.11 | Enterprise Value to EBITDA -8.84 | Shares Outstanding 228356000 | Shares Floating 177830177 |
Shares Outstanding 228356000 | Shares Floating 177830177 | ||
Percent Insiders 0.55 | Percent Institutions 53.91 |
Analyst Ratings
Rating 4.43 | Target Price 4.5 | Buy 2 | Strong Buy 4 |
Buy 2 | Strong Buy 4 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Lineage Cell Therapeutics Inc
Company Overview
History and Background
Lineage Cell Therapeutics Inc (formerly BioTime, Inc.) was founded in 1990. Initially focused on anti-aging research, the company has transitioned to developing cell therapies for unmet medical needs, particularly in ophthalmology, spinal cord injury, and oncology.
Core Business Areas
- Ophthalmology: Developing OpRegen, a retinal pigment epithelium (RPE) cell therapy for the treatment of age-related macular degeneration (AMD) with geographic atrophy (GA).
- Spinal Cord Injury: Developing OPC1, an oligodendrocyte progenitor cell therapy for acute and subacute spinal cord injury.
- Oncology: Developing VAC2, an allogeneic cancer immunotherapy based on its VAC technology platform.
- Research and Development: Conducting research to discover and develop new cell therapies.
Leadership and Structure
Brian M. Culley is the CEO. The company has a board of directors and operates with a functional organizational structure, with departments focused on R&D, clinical development, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- OpRegen: A retinal pigment epithelium (RPE) cell therapy for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA). This is Lineage's lead product candidate. Market share is not yet applicable, as the product is in clinical development. Competitors in the AMD space include Apellis Pharmaceuticals (APLS) with their product Syfovre, and Iveric Bio (ISEE) which was acquired by Astellas and is developing Avacincaptad pegol.
- OPC1: An oligodendrocyte progenitor cell therapy for acute and subacute spinal cord injury. Market share is not yet applicable, as the product is in clinical development. There are limited direct competitors due to the novel approach and challenges in spinal cord injury treatment. There are some companies trying to make treatments for spinal cord injuries, such as Neuronyx.
- VAC2: An allogeneic cancer immunotherapy based on its VAC technology platform. Market share is not yet applicable, as the product is in early stages of development. The cancer immunotherapy field is crowded, with major players like Merck (MRK) and Bristol-Myers Squibb (BMY).
Market Dynamics
Industry Overview
The cell therapy industry is rapidly growing, driven by advancements in biotechnology and regenerative medicine. It addresses unmet medical needs in areas like ophthalmology, neurology, and oncology. There is increased regulatory scrutiny and high capital investment requirements.
Positioning
Lineage Cell Therapeutics is positioned as a clinical-stage biotechnology company focused on developing and commercializing novel cell therapies. Its competitive advantage lies in its proprietary cell therapy platforms and clinical progress with OpRegen.
Total Addressable Market (TAM)
The total addressable market for cell therapies is estimated to be in the billions of dollars. For AMD with GA, the TAM is estimated to be over $10 billion annually. Lineage is positioning itself to capture a significant share of this market with OpRegen, if approved. The Spinal cord injury TAM is in the billions as well.
Upturn SWOT Analysis
Strengths
- Proprietary cell therapy platforms (e.g., pluripotent stem cell platform)
- Clinical-stage programs with promising data (especially OpRegen)
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- High cash burn rate
- Reliance on clinical trial success
- Limited commercialization experience
- Significant regulatory hurdles
Opportunities
- Positive clinical trial results leading to regulatory approvals
- Partnerships with larger pharmaceutical companies
- Expansion of cell therapy platforms to new indications
- Increased funding from grants and venture capital
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from established pharmaceutical companies
- Economic downturn impacting funding availability
Competitors and Market Share
Key Competitors
- APLS
- ISEE
- MRK
- BMY
Competitive Landscape
Lineage's competitive advantage lies in its unique cell therapy platforms, particularly OpRegen. However, it faces significant competition from larger pharmaceutical companies with greater resources and established market presence.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily driven by advancements in its clinical programs and securing funding.
Future Projections: Future growth is highly dependent on the success of OpRegen in Phase 3 clinical trials and potential regulatory approval. Analyst estimates vary, but positive outcomes could lead to significant revenue growth. The company could also expand by partnering with big pharma.
Recent Initiatives: Recent initiatives include advancing OpRegen through Phase 3 trials, seeking partnerships for its cell therapy platforms, and exploring new indications for its technologies.
Summary
Lineage Cell Therapeutics is a clinical-stage biotech company with promising cell therapy platforms, particularly OpRegen for AMD. The company's success hinges on the outcome of its Phase 3 clinical trials and ability to secure funding. Its high cash burn rate and reliance on clinical success represent significant risks. Securing partnerships would bolster its resources and market access. The company has a small market share currently compared to big pharma, but it could expand if OpRegen is approved.
Similar Companies
AGEN
Agenus Inc
AGEN
Agenus Inc
MESO
Mesoblast Ltd
MESO
Mesoblast Ltd
OCGN
Ocugen Inc
OCGN
Ocugen Inc
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- Press Releases
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on available information, which may be subject to change. Investing in biotechnology companies involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lineage Cell Therapeutics Inc
Exchange NYSE MKT | Headquaters Carlsbad, CA, United States | ||
IPO Launch date 1992-03-06 | CEO, President & Director Mr. Brian M. Culley M.A., M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 70 | Website https://www.lineagecell.com |
Full time employees 70 | Website https://www.lineagecell.com | ||
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a cell transplant program for an undisclosed indication through a gene editing collaboration, engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.